Tony Chikere
About Tony Chikere
Tony Chikere serves as the Director of Vector Process Development at Sangamo Therapeutics, Inc., where he focuses on advancing biopharmaceutical manufacturing operations. He has extensive experience in process development for viral vector entities, having held various roles at notable companies including Bayer and BioMarin Pharmaceutical.
Current Role at Sangamo Therapeutics
Tony Chikere serves as the Director of Vector Process Development at Sangamo Therapeutics, Inc., a position he has held since 2023. In this role, he focuses on leading the development of viral vector processes, aiming to enhance the efficiency and effectiveness of biopharmaceutical manufacturing operations. His responsibilities include overseeing the development, clinical evaluation, and commercialization of biologics, with a particular emphasis on reducing costs and streamlining operations.
Previous Experience in Biopharmaceuticals
Tony Chikere has extensive experience in the biopharmaceutical industry. He worked at Bayer Pharmaceuticals as an Associate Director in MSAT-BT from 2019 to 2021, where he managed process validation and continued process verification. Prior to this, he served as a Senior Manager at Bayer Pharmaceuticals from 2017 to 2019, focusing on technology transfer for GMP manufacturing. His earlier roles include positions at Bayer Healthcare, Scios, and BioMarin Pharmaceutical, where he contributed to various aspects of process development.
Educational Background
Tony Chikere holds a Doctor of Philosophy (PhD) in Biotechnology from Hamburg University of Technology, which he completed from 1996 to 2000. He also earned a Master's degree in Food Technology from the University of Ibadan, studying there from 1993 to 1994. His educational qualifications provide a strong foundation for his expertise in biopharmaceutical manufacturing and process development.
Expertise in Process Development
Tony Chikere possesses significant expertise in both upstream and downstream process development for viral vector entities. His career has been marked by a focus on improving biopharmaceutical manufacturing operations, including efforts to reduce the cost of goods and streamline processes. This expertise is critical in his current role at Sangamo Therapeutics, where he leads initiatives aimed at enhancing operational efficiency.